Comparison of Programmed Cell Death Ligand 1 Status between Core Needle Biopsy and Surgical Specimens of Triple-Negative Breast Cancer

PURPOSE: Pembrolizumab is currently used to treat advanced triple-negative breast cancer (TNBC) and high-risk early TNBC with neoadjuvant chemotherapy (NAC). The tumor-infiltrating lymphocyte (TIL) level and programmed cell death ligand 1 (PD-L1) status are predictors of response to NAC and immune c...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Hyungwook, Ahn, Sung Gwe, Bae, Soong Joon, Kim, Jee Hung, Eun, Na Lae, Lee, Yangkyu, Nahm, Ji Hae, Jeong, Joon, Cha, Yoon Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375241/
https://www.ncbi.nlm.nih.gov/pubmed/37488704
http://dx.doi.org/10.3349/ymj.2023.0090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10375241/
https://www.ncbi.nlm.nih.gov/pubmed/37488704
http://dx.doi.org/10.3349/ymj.2023.0090

Ejemplares similares